# Execution Output: phase5-package101-analysis-set-boundary-20260830 - worker_04 followup 03

## Boundary And Context Check

- **Bounded read-only review completed.** No direct edits were made to code, configs, tests, frozen candidates, source protocols, clinical reports, task records, prompts, logs, or runner-owned reports.
- No semantic model, publication control, or hydrated Agent output was called.
- Frozen identity remains:
  - Plan: `papl-e17d498106b6f71f440ff2be`
  - Package 101: `pap-b0e90038f781b39606b42df9`
  - Selected phase: `phase_ii`
- The focused test contains an existing `--dry-run` subprocess that is write-capable for preparation artifacts; no separate writer or manual edit was used.
- Result is limited to model-free source/boundary closure and is **not final clinical acceptance**.

## Work Performed

### Pass findings

1. **Exact source closure**
   - Owned: 12 refs — `body.p1179`, `body.p1186-p1196`
   - Attached: 6 refs — `body.p1180-p1185`
   - Total: 18 refs
   - `source_rows.json` order is exactly:
     `body.p1179`, `body.p1180`, …, `body.p1196`.
   - `replay-summary.json` reports:
     - `owned_count=12`
     - `attached_count=6`
     - `unit_count=18`
     - `claims_complete=false`

2. **Zero candidates and workflow bindings**
   - `required_candidate_source_refs=[]`
   - All 18 declared refs are forbidden as candidate source refs.
   - `expected_workflow_stage_ids_by_source_ref={}`.
   - Prepared owned visit/action/procedure binding maps are empty.
   - Known official rules and required procedures are empty.
   - All prepared QC rows have `agent_candidates=[]`.
   - Screening, baseline, and D1 workflow definitions remain unbound target scaffolding only.

3. **Phase II/III sample-size separation**
   - p1180-p1181 remain `phase_ii` context.
   - p1182-p1185 remain `phase_iii` read-only context.
   - Phase II design markers such as `剂量探索`, `1:1:1`, and `合计约120例` remain design facts.
   - Phase III markers such as `2:1`, `201例`, `99%`, `20%`, `最多入组420例`, `2:2:1`, `168例`, and `84例` remain isolated and are not converted into Phase II controls.

4. **Post-randomization analysis-set direction**
   - ITT remains based on randomized participants and randomized treatment assignment.
   - SS remains based on randomization, at least one dose, and post-dose safety evaluation.
   - PKCS remains based on randomization, dosing, and valid post-dose concentration data.
   - PDS remains based on randomization, dosing, and valid post-dose PD data.
   - No analysis-set criterion is inverted into screening, baseline, randomization, or D1 eligibility.

5. **p1188 and p1192 semantic safeguards**
   - p1188 preserves `基线在此表示分析内容`; it remains an ITT analysis domain, not a required baseline visit or enrollment evidence requirement.
   - p1192 preserves `剔除指统计分析集剔除`; it remains distinct from participant exclusion, withdrawal, or screening failure.
   - Exact chronology remains:
     - `盲态数据审核后`
     - `数据库锁库和揭盲之前`

6. **Adjacent-package exclusion**
   - No Package 100 refs `body.p1168-p1178` appear in the prepared prompt.
   - No Package 102 refs `body.p1197-p1205` appear.
   - Broad-context-only p1198-p1199 are absent as source refs and source rows.
   - All declared Package 101 refs are present in the prompt.

### Material defect

- **None found within the assigned bounded review.**

## Artifacts And Evidence

- Focused test:
  - `test_slice61cn_package101_analysis_set_boundary.py`
  - Result: **8 passed**
- `replay-summary.json`:
  - exact 12/6/18 closure;
  - frozen-plan lookup counts 12 owned and 6 context;
  - `claims_complete=false`;
  - `mode="dry_run_prepare"`.
- `source_rows.json`:
  - exact ordered 18-row closure;
  - owned/attached roles match the config.
- `batch.json`:
  - six read-only context refs p1180-p1185;
  - `context_is_read_only=true`;
  - empty owned workflow/action/procedure maps.
- `clinical-qc.json`:
  - all candidate lists empty;
  - `claims_complete=false`;
  - `gate.skipped=true`;
  - `parent_clinical_acceptance="pending_codex"`;
  - `runner_status="dry_run"`.
- Frozen plan and coverage manifest:
  - Package 101 ownership matches the declared 12 refs.
  - Package 102 owns p1197 and p1200-p1205.
  - p1198-p1199 have no owner.
  - Phase scopes and required source markers remain intact.

## Commands And Observations

Executed only:

```text
.venv/bin/python -m pytest -q \
  .trellis/tasks/08-22-phase5-clinical-facts-profile/research/d001-ii-phase-closure/test_slice61cn_package101_analysis_set_boundary.py
```

Observed:

```text
........                                                                 [100%]
8 passed in 1.51s
```

Minimal deterministic inspections confirmed:

- exact `12 owned / 6 attached / 18 total`;
- exact source order `body.p1179-p1196`;
- zero candidates;
- zero workflow bindings;
- `claims_complete=false`;
- Phase II/III sample-size branch separation;
- post-randomization ITT/SS/PKCS/PDS semantics;
- p1188 baseline-analysis interpretation;
- p1192 analysis-set exclusion interpretation and chronology;
- absence of Package 100/102 refs, including p1198-p1199, from the prompt.

## Blockers Or Missing Environment

- No blocker for the requested model-free verification.
- Hydrated Agent output was intentionally not produced or evaluated.
- Publication gate therefore remains skipped and `parent_clinical_acceptance` remains pending.
- No final clinical, regulatory, Patient Profile, or D001-wide acceptance claim is supported.

## Rerun Requests Or Next Step

- No rerun requested while the reviewed artifacts remain unchanged.
- Keep Package 101 at **model-free closure with zero candidates and zero workflow bindings**.
- If a hydrated run is later authorized, restrict it to the same 12 owned plus 6 read-only attached refs, require one disposition per owned ref, reject any candidate or workflow binding, and run the deterministic reject/publication gates before any acceptance decision.
- Residual operational risk: the focused test’s built-in `--dry-run` preparation step can refresh generated preparation artifacts; strict byte-level immutability should use a disposable copy in a future run.
